Upstream Bio reported positive phase 2 results for verekitug in chronic rhinosinusitis with nasal polyps and outlined a near-term...

Foghorn Therapeutics reported steady progress across its chromatin-targeting pipeline, keeping its SMARCA2 inhibitor FHD-909 on track in a Phase...

BioNTX closed 2025, signaling a step-change for the North Texas life sciences cluster: record member engagement approaching 200 organizations,...

Akari Therapeutics has outlined a 2026–2027 path to first-in-human testing of AKTX-101, a TROP2-directed antibody-drug conjugate featuring a novel...

The leadership team thought they were ahead of their drug launch schedule. Phase II data were in. The mechanism...

Mesoblast has refinanced its balance sheet with a new five-year, insider-backed credit facility of up to $125 million, drawing...

FDA has approved the once-daily Wegovy pill (oral semaglutide 25 mg) to reduce excess body weight, maintain weight reduction...

Celularity has secured up to $12 million in new financing through two binding term sheets with a single accredited...

INVO Fertility has restructured its leadership to accelerate a clinic-led growth strategy, appointing Terah Krigsvold as chief financial officer...

XOMA Royalty Corporation has amended its long-standing collaboration with Takeda, returning a majority of its royalty interest in mezagitamab...